2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial
Authors:
- 1 October 2021
- journal article
- research article
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 5 (10) , 698-707
Abstract
No abstract availableKeywords
Funding Information
- Novartis AG
This publication has 37 references indexed in Scilit:
- Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW TrialTranslational Vision Science & Technology, 2020
- Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of PrematurityJAMA Ophthalmology, 2020
- Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trialThe Lancet, 2019
- Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of PrematurityJAMA Pediatrics, 2018
- Vascular endothelial growth factor signaling is necessary for expansion of medullary microvessels during postnatal kidney developmentAmerican Journal of Physiology-Renal Physiology, 2016
- Concerns for Development After Bevacizumab Treatment of ROPPediatrics, 2016
- Regulation of lung development and regeneration by the vascular systemCellular and Molecular Life Sciences, 2015
- Pharmacokinetics of Bevacizumab and Its Effects on Serum VEGF and IGF-1 in Infants With Retinopathy of PrematurityInvestigative Ophthalmology & Visual Science, 2015
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityNew England Journal of Medicine, 2011
- VEGF in the nervous systemOrganogenesis, 2010